Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Moupali Das et al.|New England Journal of Medicine|2024Cited by 471
HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trialKhatija Ahmed, Julia D Welch, Jared M. Baeten et al.|The Lancet|2019Cited by 306
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMüge Çevik, Borisov Se, Nosipho Ngubane et al.|The Lancet Infectious Diseases|2024Cited by 60